Related references
Note: Only part of the references are listed.TRESK gene recombinant adenovirus vector inhibits capsaicin-mediated substance P release from cultured rat dorsal root ganglion neurons
Jun Zhou et al.
MOLECULAR MEDICINE REPORTS (2012)
Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2
Hyunho Yoon et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
MEK/ERK Inhibitor U0126 Increases the Radiosensitivity of Rhabdomyosarcoma Cells In vitro and In vivo by Downregulating Growth and DNA Repair Signals
Francesco Marampon et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Down-Regulation of Rad51 Expression Overcomes Drug Resistance to Gemcitabine in Human Non-Small-Cell Lung Cancer Cells
Min-Shao Tsai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis
Tri K. Nguyen et al.
LEUKEMIA RESEARCH (2010)
The small molecule Mek1/2 inhibitor U0126 disrupts the chordamesoderm to notochord transition in zebrafish
Thomas A. Hawkins et al.
BMC DEVELOPMENTAL BIOLOGY (2008)
Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma
Zheng Wang et al.
CLINICAL CANCER RESEARCH (2008)
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
Jer-Yen Yang et al.
NATURE CELL BIOLOGY (2008)
Cytotoxic therapy for advanced pancreatic adenocarcinoma
Eileen M. O'Reilly et al.
SEMINARS IN ONCOLOGY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis
Alireza Mirmohammadsadegh et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma
Krishdeep S. Chadha et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Targeting the ERK signaling pathway in cancer therapy
M Kohno et al.
ANNALS OF MEDICINE (2006)
Inhibition of Src tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells
MS Duxbury et al.
CLINICAL CANCER RESEARCH (2004)
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours
S Vicent et al.
BRITISH JOURNAL OF CANCER (2004)
Requirement for ERK activation in cisplatin-induced apoptosis
XT Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
